Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127850 | 1.00 | HTR6 (0.56) | HTR6L3MBTL3L3MBTL1PHGDHMGLL | |
| SCHEMBL21422636 | 0.97 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1PHGDHMGLL | |
| SCHEMBL60131 | 0.97 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1PHGDHMGLL | |
| SCHEMBL2107230 | 0.97 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1PHGDHMGLL | |
| SCHEMBL728754 | 0.97 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1PHGDHMGLL | |
| SCHEMBL24782761 | 0.97 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1PHGDHMGLL | |
| SCHEMBL21057384 | 0.97 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1PHGDHMGLL | |
| SCHEMBL22216666 | 0.97 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1PHGDHMGLL | |
| SCHEMBL21057351 | 0.97 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1PHGDHMGLL | |
| SCHEMBL1828721 | 0.97 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1PHGDHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117720517-A | AR inhibitor, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-03-19 | — | — | CN | claimed |
| WO-2024012570-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 西藏海思科制药有限公司 | 2024-01-18 | — | — | WO | claimed |
| WO-2023232133-A1 | COMPOUND FOR INHIBITING OR DEGRADING BCL6 AND USE THEREOF IN PHARMACEUTICS | 西藏海思科制药有限公司 | 2023-12-07 | — | — | WO | claimed |
| CN-115703730-A | Sulfonylurea compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | claimed |
| CN-114920746-A | BTK (BTK inhibitory or degrading agent) and application thereof in medicine | 四川海思科制药有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-108290055-B | Oxime compounds as agonists of the muscle M1 and/or M4 receptor | 赫普泰雅治疗有限公司 | 2021-05-14 | — | — | CN | claimed |
| EP-2318408-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-17 | — | — | EP | claimed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | claimed |
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | claimed |
| EP-2778155-A1 | 2-aminopyridine derivatives useful as kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2014-09-17 | — | — | EP | claimed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | claimed |
| WO-2010011772-A2 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | claimed |
| WO-2010011756-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | claimed |
| WO-2010011762-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | claimed |
| WO-2010011768-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | claimed |
| EP-2121613-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | claimed |
| WO-2008094992-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-07 | — | — | WO | claimed |
| US-20060035920-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2005118583-A1 | 2, 5-DIHYDRO-PYRAZOLO`4, 3-C!QUINOLIN-4-ONES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035920-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | HTR6 3259/4885L3MBTL3 1696/4885L3MBTL1 733/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | HTR6 3265/4885L3MBTL3 2612/4885L3MBTL1 2582/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | HTR6 3265/4885L3MBTL3 2612/4885L3MBTL1 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.